{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=HEC+Placebo", "query": { "intervention": "HEC Placebo" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 30, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=HEC+Placebo&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-05T03:40:46.187Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00490152", "title": "Microbicides Acceptability Among Sexually Active Young Women", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Automated diary system", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of North Carolina, Chapel Hill", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "24 Years", "sex": "FEMALE", "summary": "18 Years to 24 Years · Female only" }, "enrollment_count": 59, "start_date": "2007-08", "completion_date": "2009-11", "has_results": false, "last_update_posted_date": "2017-02-28", "last_synced_at": "2026-09-05T03:40:46.187Z", "location_count": 2, "location_summary": "Tampa, Florida • Pittsburgh, Pennsylvania", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00490152" }, { "nct_id": "NCT00442910", "title": "Safety and Acceptability of SPL7013 Gel (VivaGel™) in Sexually Active Women", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "3% SPL7013 Gel (VivaGel)", "type": "DRUG" }, { "name": "Placebo Gel", "type": "DRUG" }, { "name": "HEC Placebo Gel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Starpharma Pty Ltd", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "24 Years", "sex": "FEMALE", "summary": "18 Years to 24 Years · Female only" }, "enrollment_count": 61, "start_date": "2007-07", "completion_date": "2009-12", "has_results": false, "last_update_posted_date": "2010-06-24", "last_synced_at": "2026-09-05T03:40:46.187Z", "location_count": 2, "location_summary": "Tampa, Florida • Pittsburgh, Pennsylvania", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00442910" }, { "nct_id": "NCT03578081", "title": "Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Malignant Neoplasm" ], "interventions": [ { "name": "Palonosetron Hydrochloride", "type": "DRUG" }, { "name": "Ondansetron Hydrochloride", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Fosaprepitant Dimeglumine", "type": "DRUG" }, { "name": "Olanzapine", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 690, "start_date": "2018-11-20", "completion_date": "2023-05-01", "has_results": true, "last_update_posted_date": "2025-04-06", "last_synced_at": "2026-09-05T03:40:46.187Z", "location_count": 565, "location_summary": "Birmingham, Alabama • Fairbanks, Alaska • Kingman, Arizona + 372 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Fairbanks", "state": "Alaska" }, { "city": "Kingman", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT03578081" }, { "nct_id": "NCT04370548", "title": "DARE-BV1 in the Treatment of Bacterial Vaginosis (DARE-BVFREE)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Bacterial Vaginosis" ], "interventions": [ { "name": "DARE-BV1clindamycin phosphate vaginal gel, 2%", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Daré Bioscience, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "FEMALE", "summary": "12 Years and older · Female only" }, "enrollment_count": 307, "start_date": "2020-06-16", "completion_date": "2020-12-07", "has_results": true, "last_update_posted_date": "2022-12-08", "last_synced_at": "2026-09-05T03:40:46.187Z", "location_count": 10, "location_summary": "Tucson, Arizona • Denver, Colorado • Miami, Florida + 6 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Denver", "state": "Colorado" }, { "city": "Miami", "state": "Florida" }, { "city": "Sunrise", "state": "Florida" }, { "city": "West Palm Beach", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04370548" }, { "nct_id": "NCT01830348", "title": "Phase III Study to Evaluate Efficacy and Safety of DSC127 in Diabetic Foot Ulcers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetic Foot Ulcers" ], "interventions": [ { "name": "DSC127", "type": "DRUG" }, { "name": "placebo vehicle gel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Integra LifeSciences Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 266, "start_date": "2013-02", "completion_date": "2015-12", "has_results": false, "last_update_posted_date": "2017-12-12", "last_synced_at": "2026-09-05T03:40:46.187Z", "location_count": 25, "location_summary": "Mobile, Alabama • Fair Oaks, California • Fresno, California + 22 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Fair Oaks", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Pismo Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01830348" }, { "nct_id": "NCT01804023", "title": "Biomarkers of Protocol Compliance and Product Adherence", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "HIV Prevention" ], "interventions": [ { "name": "HEC placebo gel applicators", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "CONRAD", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "FEMALE", "summary": "18 Years to 50 Years · Female only" }, "enrollment_count": 40, "start_date": "2013-03", "completion_date": "2013-09", "has_results": false, "last_update_posted_date": "2013-10-30", "last_synced_at": "2026-09-05T03:40:46.187Z", "location_count": 1, "location_summary": "Norfolk, Virginia", "locations": [ { "city": "Norfolk", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01804023" }, { "nct_id": "NCT01277640", "title": "Male Tolerance Study of Dapivirine Gel Following Multiple Topical Penile Exposures", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Topical Penile Exposures" ], "interventions": [ { "name": "dapivirine", "type": "DRUG" }, { "name": "matched placebo", "type": "DRUG" }, { "name": "universal placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "International Partnership for Microbicides, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 48, "start_date": "2011-03", "completion_date": "2011-07", "has_results": false, "last_update_posted_date": "2017-09-08", "last_synced_at": "2026-09-05T03:40:46.187Z", "location_count": 2, "location_summary": "Birmingham, Alabama • Pittsburgh, Pennsylvania", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01277640" }, { "nct_id": "NCT03239483", "title": "Safety and Pharmacokinetic Study of Dapivirine Gel (0.05%) Administered Rectally to HIV-1 Seronegative Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Dapivirine gel", "type": "DRUG" }, { "name": "Placebo gel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "45 Years", "sex": "ALL", "summary": "18 Years to 45 Years" }, "enrollment_count": 28, "start_date": "2017-10-26", "completion_date": "2018-09-20", "has_results": true, "last_update_posted_date": "2021-10-19", "last_synced_at": "2026-09-05T03:40:46.187Z", "location_count": 2, "location_summary": "Birmingham, Alabama • Pittsburgh, Pennsylvania", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03239483" }, { "nct_id": "NCT01849965", "title": "Phase 3 Study Evaluating Efficacy and Safety of DSC127 Compared With Vehicle and With Standard-of-care in Diabetic Foot Ulcers", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetic Foot Ulcers" ], "interventions": [ { "name": "DSC127", "type": "DRUG" }, { "name": "placebo vehicle gel", "type": "DRUG" }, { "name": "Standard of Care gel, Aquasite", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Integra LifeSciences Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 396, "start_date": "2013-04", "completion_date": "2015-12", "has_results": false, "last_update_posted_date": "2017-12-12", "last_synced_at": "2026-09-05T03:40:46.187Z", "location_count": 33, "location_summary": "Mesa, Arizona • Phoenix, Arizona • Castro Valley, California + 25 more", "locations": [ { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01849965" }, { "nct_id": "NCT02116530", "title": "Antiemetic Therapy With or Without Olanzapine in Preventing Chemotherapy-Induced Nausea and Vomiting in Patients With Cancer Receiving Highly Emetogenic Chemotherapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hematopoietic/Lymphoid Cancer", "Nausea and Vomiting", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "Olanzapine", "type": "DRUG" }, { "name": "Chemotherapy (cisplatin or cyclophosphamide and doxorubicin)", "type": "DRUG" }, { "name": "Antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant)", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Alliance for Clinical Trials in Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 401, "start_date": "2014-08-20", "completion_date": "2017-06-15", "has_results": true, "last_update_posted_date": "2025-01-28", "last_synced_at": "2026-09-05T03:40:46.187Z", "location_count": 177, "location_summary": "Anchorage, Alaska • Burbank, California • Dublin, California + 109 more", "locations": [ { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT02116530" } ] }